Read & Win: Managing Biotechnology – From Science to Market in the Digital Age

  • Managing Biotechnology –  From Science to Market in the Digital AgeManaging Biotechnology – From Science to Market in the Digital Age
  • Managing Biotechnology –  From Science to Market in the Digital Age
  • Dr. Francoise Simon is Professor Emerita at Columbia University and Senior Faculty, Mount Sinai School of Medicine. Her teaching focuses on graduate and executive programs and won the Chandler Award for Commitment to Excellence from the Columbia Business School.
  • Glen Giovannetti is a partner at Ernst & Young LLP and the EY Global Biotechnology Leader. He has over 25 years of experience serving clients in the biopharmaceutical industry on a range of strategic issues.

Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide.

Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies.


Interviewer: What is your main focus in research, what is your main scientific interest?

Professor at Columbia and Mount Sinai , teaching and researching the digital transformation of biotechnology, including optimization of R&D, clinical trials, marketing and communications with new digital tools (devices such as Apple Watch and Fitbit for remote drug monitoring and communication with patients, data analytics for research, etc). Also analysis of the new role of Infotechs such as Apple, Alphabet, Amazon and IBM in enabling (or possibly also disrupting) healthcare.

Interviewer: What was the reason to write the book and what is the target audience?
Widespread company demand for  this topic, which is also under-researched in the academic literature. The book is designed as a roadmap for startups as well as biopharmas, it is based on over 150 expert interviews, and it includes practical cases, contributed by companies such as BMS, Celgene, Regeneron and Alnylam.
Interviewer: What knowledge is prerequisite for the book and what is the structure like?
A health professional audience is most relevant, but the book cab be read also by a general audience interested in new technologies.

Book structure is described in the attached announcement and table of contents.

Interviewer: What is the most difficult part of the way from science to market? How did and does the digitalization change the field of biotechnology?
Given the high attrition of pipeline compounds, bringing a compound from the preclinical to human clinical stage, and getting through these clinicals successfully, is the most difficult development step. Analytics tools such as IBM Watson Health may act as enablers, by sorting through multiple databases.
Simon, F. / Giovannetti, G.
Managing Biotechnology
From Science to Market in the Digital Age
ISBN: 978-1-119-21617-9

Also available in electronic formats!

Other book presentations




Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.